This gatekeeping approach means patients with A1C levels between 5.7% and 6.4%the clinical definition of prediabetesfall outside covered indications, even though clinical evidence supports early intervention
You may be experiencing: Difficulty losing weight despite consistent habits Weight regain after previous success Increased hunger or cravings Low energy or inconsistent results Frustration with programs that do not last These patterns are often not random
The effects of tirzepatide on body weight control have also been confirmed in non-diabetic individuals in the SURMOUNT-1 study, where treatment with tirzepatide 1015 mg was associated with an average weight loss of approximately 20% at 72 weeks, exceeding 25% in one third of the patients
A patient trying to heal from an injury still needs a proper diagnosis, appropriate rehabilitation, progressive loading, adequate protein, sleep, hydration, metabolic support, and realistic timelines
Measurement of SCFAs in stool reflects microbial metabolic activity, with butyrate, acetate, and propionate supporting immune tolerance and anti-inflammatory signaling
Noninvasive biomarkers in pediatric nonalcoholic fatty liver disease
